Sylvant 400 mg prašek za koncentrat za raztopino za infundiranje
Siltuksimab
Composition and organoleptic properties
| Name | Role | Strength | Strength expression |
|---|---|---|---|
| siltuksimab | — | 400 mg/1 prašek | — |
Organoleptic description—
Drug status
This medicine is subject to additional safety monitoring. You can report any suspected adverse reactions yourself.
The medicinal product is present in wholesale distribution.
Last drug update date:9. 7. 2026